Private Prescription Program Medicines

The Novartis Private Prescription Program is currently servicing the below medicines.

If you do not see your prescribed medicine mentioned in the list, please check later as we are including additional medicines throughout 2025.

This page contains approved Product Information (PI) and Consumer Medicine Information (CMI) for Novartis Pharmaceuticals products in Australia.

This information only applies to Novartis Pharmaceuticals products available in Australia and does not apply to Novartis products in other countries.

If you are a healthcare professional with a valid AHPRA number and would like to learn more about our medicines, please click here: Homepage - Guest | Novartis Pro Australia

Aimovig (erenumab)

Artige (methylphenidate hydrochloride)

Cosentyx (secukinumab)

Entresto (sacubitril with valsartan)

Glivec (imatinib)

Jakavi (ruxolitinib phosphate)

Jadenu (deferasirox)

Kesimpta (ofatumumab)

Kisqali (ribociclib succinate)

Leqvio (inclisiran)

Lucentis (ranibizumab)

Mekinist (trametinib)

Omtralo (sacubitril/valsartan)

Piqray (alpelisib)

Revolade (eltrombopag olamine)

Ritalin (methylphenidate hydrochloride)

Rydapt (midostaurin)

Scemblix (asciminib hydrochloride)

Tafinlar (dabrafenib)

Tasigna (nilotinib)

Xolair (omalizumab)